Injection of Glatiramer Acetate Depot Results in T1 and T2 Lesion Reduction in Relapsing MS.

Published Date: 01 Mar 2023

Secondary results from a phase 3 study show that patients with multiple sclerosis receiving glatiramer acetate depot therapy have significantly fewer new T1 enhancing lesions and new, enlarging hyperintense T2 lesions.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

TRK Inhibitor Active in Treatment-Refractory Glioblastoma

2.

Hydroxyurea Shows Some Benefits in Milder Sickle Cell Disease

3.

In high-risk muscle invasive urothelial cancer, adjuvant pembrolizumab improves disease-free survival.

4.

Research finds COVID-19 mRNA vaccine sparks immune response to fight cancer

5.

VP Nominee Medical Records Breached; Queen Elizabeth's Cancer; Galaxy Gas Whippets


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot